Safety Profile of Nivolumab in Japanese NSCLC Pts: Interim Results from Post-marketing All-Case Surveillance in Japan

被引：0
|
作者：
Genma, Akihiko [1 ]
Nakanishi, Yoichi [2 ]
Nakagawa, Kazuhiko [3 ]
Yamamoto, Nobuyuki [4 ]
Saito, Takeshi [5 ]
Tahara, Yasuhiro [5 ]
Ohe, Yuichiro [6 ]
机构：
[1] Nippon Med Sch, Tokyo, Japan
[2] Kyushu Univ, Sch Med, Fukuoka, Japan
[3] Kindai Univ, Sch Fac Med, Higashiosaka, Osaka, Japan
[4] Wakayama Med Univ, Wakayama, Japan
[5] Ono Pharmaceut CO LTD, Osaka, Japan
[6] Natl Canc Ctr, Tokyo, Japan
来源：
ANNALS OF ONCOLOGY | 2017年 / 28卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
SPS-9
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Safety Profile of Nivolumab in Japanese NSCLC Pts: Interim Results from Post-marketing All-Case Surveillance in Japan
    Genma, Akihiko
    Nakanishi, Yoichi
    Nakagawa, Kazuhiko
    Yamamoto, Nobuyuki
    Saito, Takeshi
    Tahara, Yasuhiro
    Ohe, Yuichiro
    [J]. ANNALS OF ONCOLOGY, 2017, 28 : 75 - 75
  • [2] Real-world safety of nivolumab in patients with non-small cell lung cancer (NSCLC) in Japan: Interim summary of post-marketing all-case surveillance
    Ohe, Y.
    Gemma, A.
    Nakagawa, K.
    Yamamoto, N.
    Saito, T.
    Akamatsu, A.
    Kuwano, K.
    Nakanishi, Y.
    [J]. ANNALS OF ONCOLOGY, 2018, 29
  • [3] Safety Profile of Ixazomib in Patients with Relapsed/Refractory Multiple Myeloma in Japan: An All-case Post-marketing Surveillance
    Kakimoto, Yoshihide
    Hoshino, Miyako
    Hashimoto, Mikiko
    Hiraizumi, Masaya
    Shimizu, Kohei
    Chou, Takaaki
    [J]. INTERNAL MEDICINE, 2022, 61 (09) : 1337 - 1343
  • [4] Safety of baricitinib in Japanese patients with rheumatoid arthritis: the 2020 interim report from all-case post-marketing surveillance in clinical practice
    Fujii, T.
    Atsumi, T.
    Okamoto, N.
    Takahashi, N. T. N.
    Tamura, N.
    Nakajima, A.
    Matsuno, H.
    Tsujimoto, N.
    Nishikawa, A.
    Ishii, T.
    Takeuchi, T.
    Kuwana, M.
    Takagi, M.
    Larsson, E.
    [J]. SCANDINAVIAN JOURNAL OF RHEUMATOLOGY, 2021, 50 : 25 - 25
  • [5] Drug use investigation on the safety and efficacy of tigecycline in Japan (all-case post-marketing surveillance)
    Ohashi, Takahisa
    Sugiyama, Noriko
    Watanabe, Toshiya
    Uryu, Taku
    Yoshinaga, Yukari
    [J]. JOURNAL OF INFECTION AND CHEMOTHERAPY, 2022, 28 (07) : 866 - 874
  • [6] Infection Events in Japanese Patients with Rheumatoid Arthritis Treated with Tofacitinib: Interim All-Case Post-Marketing Surveillance
    Tamura, Naoto
    Kuwana, Masataka
    Atsumi, Tatsuya
    Takei, Syuji
    Harigai, Masayoshi
    Fujii, Takao
    Matsuno, Hiroaki
    Mimori, Tsuneyo
    Momohara, Shigeki
    Yamamoto, Kazuhiko
    Takasaki, Yoshinari
    Nomura, Kazuto
    Endo, Yutaka
    Hirose, Tomohiro
    Morishima, Yosuke
    Sugiyama, Naonobu
    Yoshii, Noritoshi
    Takagi, Michiaki
    [J]. ARTHRITIS & RHEUMATOLOGY, 2018, 70
  • [7] Malignancy in Japanese Patients with Rheumatoid Arthritis Treated with Tofacitinib: Interim Analysis of All-Case Post-Marketing Surveillance
    Tamura, Naoto
    Kuwana, Masataka
    Atsumi, Tatsuya
    Takei, Syuji
    Harigai, Masayoshi
    Fujii, Takao
    Matsuno, Hiroaki
    Mimori, Tsuneyo
    Momohara, Shigeki
    Yamamoto, Kazuhiko
    Takasaki, Yoshinari
    Nomura, Kazuto
    Endo, Yutaka
    Hirose, Tomohiro
    Morishima, Yosuke
    Sugiyama, Naonobu
    Yoshii, Noritoshi
    Takagi, Michiaki
    [J]. ARTHRITIS & RHEUMATOLOGY, 2018, 70
  • [8] Post-marketing surveillance of erlotinib for NSCLC in Japan: Interim analyses of 3,488 patients (Pts)
    Ohe, Y.
    Fukuoka, M.
    Kudoh, S.
    Nakagawa, K.
    Johkoh, T.
    Ando, M.
    Yamazaki, N.
    Takemoto, S.
    Seki, A.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [9] Safety and effectiveness of baricitinib for rheumatoid arthritis in Japanese clinical practice: 24-week results of all-case post-marketing surveillance
    Takagi, Michiaki
    Atsumi, Tatsuya
    Matsuno, Hiroaki
    Tamura, Naoto
    Fujii, Takao
    Okamoto, Nami
    Takahashi, Nobunori
    Nakajima, Atsuo
    Nakajima, Ayako
    Tsujimoto, Naoto
    Nishikawa, Atsushi
    Ishii, Taeko
    Takeuchi, Tsutomu
    Kuwana, Masataka
    [J]. MODERN RHEUMATOLOGY, 2023, 33 (04) : 647 - 656
  • [10] Safety and Effectiveness of Natalizumab: First Report of Interim Results of Post-Marketing Surveillance in Japan
    Saida T.
    Yokoyama K.
    Sato R.
    Makioka H.
    Iizuka Y.
    Hase M.
    Ling Y.
    Torii S.
    [J]. Neurology and Therapy, 2017, 6 (2) : 197 - 211
12345